Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-01-2016 | Original Article – Clinical Oncology

Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO)

Authors: C. Kahl, R. Krahl, C. Becker, H. K. Al-Ali, H. G. Sayer, A. Schulze, M. Herold, M. Hänel, S. Scholl, A. Hochhaus, L. Uharek, G. Maschmeyer, D. Haehling, C. Junghanß, N. Peter, D. Kämpfe, E. Kettner, T. Heinicke, T. Fischer, U. Kreibich, H.-H. Wolf, D. Niederwieser

Published in: Journal of Cancer Research and Clinical Oncology | Issue 1/2016

Abstract

Introduction

Treatment of patients (pts) with acute myelogenous leukaemia (AML) above 60 years remains a challenge. We report long-term follow-up of the AML97 study, where pts were registered at diagnosis and received treatment dependent on their comorbidities: dose-intense cytarabine (AraC) and anthracycline in the curative arm, and low-dose chemotherapy in the palliative arm or best supportive care.

Materials and Methods

A total of 618 pts were enrolled in this protocol (curative 471, palliative 115 and supportive 32). In the curative arm, complete remission (CR) was obtained in 66.8 % of pts and the estimated probability of being alive at 2 years was 0.30 (±0.02 SE). In multivariate analysis, gender (p = 0.005), performance status (p = 0.04) and cytogenetics (p = 0.002) were significant factors for CR. With a median follow-up of 10 (range 0.1–11.8) years, the estimated probability of being event-free after 2 and 5 years according to cytogenetics was 0.48 ± 0.11 and 0.48 ± 0.11 for favourable, 0.20 ± 0.03 and 0.09 ± 0.03 for normal, 0.18 ± 0.06 and 0.10 ± 0.05 for other standard risk and 0.10 ± 0.03 and 0.05 ± 0.02 for unfavourable karyotypes, respectively. The median survival time for pts treated with palliative chemotherapy was 54 and 11 days with best supportive care only.

Conclusion

In conclusion, treatment of older AML pts with dose-intense AraC is feasible in the majority of pts and induces high rates of CR. Nevertheless, except for favourable karyotype, OS and event-free survival remain low. These results need to be viewed in relation to the new modalities including stem cell transplantation following non-myeloablative conditioning, epigenetic and molecular therapies.

Al-Ali HK, Jaekel N, Junghanss C, Maschmeyer G, Krahl R, Cross M, Hoppe G, Niederwieser D (2012) Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study. Leuk Lymphoma 53:110–117PubMedCrossRef

Al-Ali HK, Jaekel N, Niederwieser D (2014) The role of hypomethylating agents in the treatment of elderly patients with AML. J Geriatr Oncol 5:89–105PubMedCrossRef

Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, Patil SR, Davey FR, Berg DT, Schiffer CA et al (1998) Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58:4173–4179PubMed

Buchner T, Hiddemann W, Wormann B, Loffler H, Gassmann W, Haferlach T, Fonatsch C, Haase D, Schoch C, Hossfeld D et al (1999) Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood 93:4116–4124PubMed

Buchner T, Hiddemann W, Schoch C, Haferlach T, Sauerland MC, Heinecke A (2001) Acute myeloid leukaemia (AML): treatment of the older patient. Best Pract Res Clin Haematol 14:139–151PubMedCrossRef

Buchner T, Hiddemann W, Berdel W, Wormann B, Schoch C, Loffler H, Haferlach T, Schumacher A, Staib P, Balleisen L et al (2002) Acute myeloid leukemia: treatment over 60. Rev Clin Exp Hematol 6:46–59PubMedCrossRef

Buchner T, Berdel WE, Schoch C, Haferlach T, Serve HL, Kienast J, Schnittger S, Kern W, Tchinda J, Reichle A et al (2006) Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol 24:2480–2489PubMedCrossRef

Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS et al (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100:4325–4336PubMedCrossRef

Catovsky D, Matutes E (1992) The classification of acute leukaemia. Leukemia 6(Suppl 2):1–6PubMed

Catovsky D, Matutes E, Buccheri V, Shetty V, Hanslip J, Yoshida N, Morilla R (1991) A classification of acute leukaemia for the 1990s. Ann Hematol 62:16–21PubMedCrossRef

Champlin R (2013) Reduced intensity allogeneic hematopoietic transplantation is an established standard of care for treatment of older patients with acute myeloid leukemia. Best Pract Res Clin Haematol 26:297–300PubMedCrossRef

Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, Brunning R, Gale RP, Grever MR, Keating MJ et al (1990) Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8:813–819PubMed

Feinstein LC, Sandmaier BM, Hegenbart U, McSweeney PA, Maloney DG, Gooley TA, Maris MB, Chauncey TR, Bruno B, Appelbaum FR et al (2003) Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. Br J Haematol 120:281–288PubMedCrossRef

Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE (2001) Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 98:1302–1311PubMedCrossRef

Green S, Weiss GR (1992) Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10:239–253PubMedCrossRef

Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A et al (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood 92:2322–2333PubMed

Gyurkocza B, Storb R, Storer BE, Chauncey TR, Lange T, Shizuru JA, Langston AA, Pulsipher MA, Bredeson CN, Maziarz RT et al (2010) Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol 28:2859–2867PubMedPubMedCentralCrossRef

Hiddemann W, Schleyer E, Unterhalt M, Zuhlsdorf M, Rolf C, Reuter C, Kewer U, Uhrmeister C, Wormann B, Buchner T (1992) Differences in the intracellular pharmacokinetics of cytosine arabinoside (AraC) between circulating leukemic blasts and normal mononuclear blood cells. Leukemia 6:1273–1280PubMed

Jaffe ES (2001) Pathology and genetics of tumors of haematopoietic and lymphoid tissues. In: Jaffe ES, Harris NL, Stein JE, Variakojis D (eds) World Health Organization classification of tumors. IARC Press, Lyon

Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, Lindsley RC, Mermel CH, Burtt N, Chavez A et al (2014) Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371:2488–2498PubMedPubMedCentralCrossRef

Kahl C, Storer B, Mielcarek M, Maris M, Sandmaier BM, Maloney D, Chauncey T, Niederwieser D, McSweeney P, Bruno B et al (2005) Relapse risk after nonmyeloablative hematopoietic cell transplantation for malignant diseases. Blood 110(7):2744–2748CrossRef

Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R, Cermak J et al (2012) Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30:2670–2677PubMedCrossRef

Karnofsky D, Burchenal J (1949) The Clinical Evaluation of Chemotherapeutic Agents in Cancer. In: MacLeod C (ed) Evaluation of Chemotherapeutic Agents. Columbia University Press, New York

Kern W, Aul C, Maschmeyer G, Schonrock-Nabulsi R, Ludwig WD, Bartholomaus A, Bettelheim P, Wormann B, Buchner T, Hiddemann W (1998) Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison. Leukemia 12:1049–1055PubMedCrossRef

Kern W, Schoch C, Haferlach T, Braess J, Unterhalt M, Wormann B, Buchner T, Hiddemann W (2000) Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities. Leukemia 14:226–231PubMedCrossRef

Lopez A, de la Rubia J, Martin G, Martinez J, Cervera J, Jarque I, Sempere A, Plume G, Saavedra S, Regadera A et al (2001) Recent improvements in outcome for elderly patients with de novo acute myeloblastic leukemia. Leuk Res 25:685–692PubMedCrossRef

Mantovani L, Hasenclever D, Krahl R, Ponisch W, Herold M, Pasold R, Fiedler F, Dolken G, Kampfe D, Schmoll HJ et al (2002) Intermediate-dose cytarabine treatment delivered at moderate infusion rates for de novo acute myeloid leukemia-results of a phase I-II study. Leuk Lymphoma 43:265–274PubMedCrossRef

Mengis C, Aebi S, Tobler A, Dahler W, Fey MF (2003) Assessment of differences in patient populations selected for excluded from participation in clinical phase III acute myelogenous leukemia trials. J Clin Oncol 21:3933–3939PubMedCrossRef

Mitelman F (1995) An international system for human cytogenetic nomenclature. Karger, Basel

Nelson RP Jr, Yu M, Schwartz JE, Robertson MJ, Hromas R, Fausel CA, Vance GH, Dlouhy SR, Baute JA, Cox EA et al (2010) Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia. Bone Marrow Transplant 45:1300–1308PubMedCrossRef

Othus M, Kantarjian H, Petersdorf S, Ravandi F, Godwin J, Cortes J, Pierce S, Erba H, Faderl S, Appelbaum FR et al (2014) Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson. Leukemia 28:289–292PubMedPubMedCentralCrossRef

Pleyer L, Stauder R, Burgstaller S, Schreder M, Tinchon C, Pfeilstocker M, Steinkirchner S, Melchardt T, Mitrovic M, Girschikofsky M et al (2013) Azacitidine in patients with WHO-defined AML—results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group. J Hematol Oncol 6:32PubMedPubMedCentralCrossRef

Plunkett W, Liliemark JO, Estey E, Keating MJ (1987a) Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C. Semin Oncol 14:159–166PubMed

Plunkett W, Nowak B, Keating MJ (1987b) Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy. Cancer Treat Rep 71:479–483PubMed

Schaich M, Illmer T, Aulitzky W, Bodenstein H, Clemens M, Neubauer A, Repp R, Schakel U, Soucek S, Wandt H et al (2002) Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 years. Haematologica 87:808–815PubMed

Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P, Lee EJ, Moore JO, Powell BL, Schiffer CA (1995) Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med 332:1671–1677PubMedCrossRef

Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman PP, Lee EJ, Moore JO, Powell BL, Baer MR et al (2001) Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 98:548–553PubMedCrossRef

Thepot S, Itzykson R, Seegers V, Recher C, Raffoux E, Quesnel B, Delaunay J, Cluzeau T, Marfaing KA, Koka A, Stamatoullas A et al (2014) Azacitidine in untreated acute myeloid leukemia: a report on 149 patients. Am J Hematol 89(4):410–416PubMedCrossRef

Wang ES (2014) Treating acute myeloid leukemia in older adults. Hematol Am Soc Hematol Educ Program 2014:14–20CrossRef

Title: Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO)
Authors: C. Kahl
R. Krahl
C. Becker
H. K. Al-Ali
H. G. Sayer
A. Schulze
M. Herold
M. Hänel
S. Scholl
A. Hochhaus
L. Uharek
G. Maschmeyer
D. Haehling
C. Junghanß
N. Peter
D. Kämpfe
E. Kettner
T. Heinicke
T. Fischer
U. Kreibich
H.-H. Wolf
D. Niederwieser
Publication date: 01-01-2016
Publisher: Springer Berlin Heidelberg
Published in: Journal of Cancer Research and Clinical Oncology / Issue 1/2016
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-015-2045-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Materials and Methods

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2016

Expression of activation-induced cytidine deaminase is associated with a poor prognosis of diffuse large B cell lymphoma patients treated with CHOP-based chemotherapy

Reverse chemomodulatory effects of the SIRT1 activators resveratrol and SRT1720 in Ewing’s sarcoma cells: resveratrol suppresses and SRT1720 enhances etoposide- and vincristine-induced anticancer activity

Riproximin modulates multiple signaling cascades leading to cytostatic and apoptotic effects in human breast cancer cells

TGF-β1-induced miR-202 mediates drug resistance by inhibiting apoptosis in human osteosarcoma

How staging of thin melanoma is changed after the introduction of TNM 7th edition: a population-based analysis

Systemic lupus erythematosus and malignancies risk

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials